Premium
Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.
Author(s) -
Challenor VF,
Waller DG,
Hayward RA,
Griffin MJ,
Roath OS
Publication year - 1991
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1991.tb05565.x
Subject(s) - enalapril , medicine , placebo , raynaud disease , skin temperature , clinical endpoint , anesthesia , cardiology , angiotensin converting enzyme , randomized controlled trial , blood pressure , dermatology , pathology , alternative medicine
1. The efficacy and acceptability of enalapril were assessed in a double‐blind, randomised, placebo controlled cross‐over study in 21 patients with primary Raynaud's phenomenon. 2. Skin temperature was assessed by thermocouples in response to a 15 degrees C cold water challenge as an index of digital blood flow. 3. Following enalapril there were no significant changes in the number and severity of Raynaud's attacks, and no subjective benefit from treatment as measured by visual analogue scales, 5 point rating scales, and skin temperature response to cold challenge when compared with placebo. 4. Enalapril in a dose of 20 mg daily is ineffective in the management of primary Raynaud's phenomenon.